We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Draft Guidance Comments: RRAs Beneficial, But Need More Explanation
Draft Guidance Comments: RRAs Beneficial, But Need More Explanation
The FDA questioned and answered virtually all aspects of Remote Regulatory Assessments (RRA) in an 18-page revised draft guidance issued last January, and the comments on the Q&A document have arrived with more questions of their own.